Amgen Inc. Files 8-K on Financials

Ticker: AMGN · Form: 8-K · Filed: 2024-05-02T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-K, results-of-operations

Related Tickers: AMGN

TL;DR

Amgen filed an 8-K on May 2, 2024, updating on financial condition and results.

AI Summary

On May 2, 2024, Amgen Inc. filed an 8-K report detailing its financial results and condition. The filing includes financial statements and exhibits related to its operations. Amgen Inc. is incorporated in Delaware and its principal executive offices are located in Thousand Oaks, California.

Why It Matters

This filing provides investors with crucial updates on Amgen's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or unusual risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Amgen Inc.?

The primary purpose of this 8-K filing is to report on Amgen Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.

When was this 8-K report filed by Amgen Inc.?

This 8-K report was filed on May 2, 2024.

Where are Amgen Inc.'s principal executive offices located?

Amgen Inc.'s principal executive offices are located at One Amgen Center Drive, Thousand Oaks, California 91320-1799.

In which state is Amgen Inc. incorporated?

Amgen Inc. is incorporated in Delaware.

What is the SIC code for Amgen Inc.?

The Standard Industrial Classification (SIC) code for Amgen Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

From the Filing

0000318154-24-000018.txt : 20240502 0000318154-24-000018.hdr.sgml : 20240502 20240502160358 ACCESSION NUMBER: 0000318154-24-000018 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240502 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 24908054 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 8-K 1 amgn-20240502.htm 8-K amgn-20240502 0000318154 false 0000318154 2024-05-02 2024-05-02 0000318154 exch:XNGS us-gaap:CommonStockMember 2024-05-02 2024-05-02 0000318154 exch:XNGS amgn:A2.00SeniorNotesDue2026Member 2024-05-02 2024-05-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024  - Amgen Inc. (Exact name of registrant as specified in its charter)    Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Amgen Center Drive   Thousand Oaks California 91320-1799 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code ( 805 ) 447-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value AMGN The Nasdaq Stock Market LLC 2.000% Senior Notes due 2026 AMGN26 The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. First Quarter 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On May 2, 2024 , the Company issued a press release announcing its unaudited results of operations for the three months ended March 31, 2024, and its unaudited financial position as of March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the

View on Read The Filing